Press Releases
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
OCALA, Fla., April 25, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
OCALA, Fla., April 18, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM...
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
OCALA, Fla., April 15, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM") today announced that Charles Lapp, MD, is joining the company to help lead its efforts to develop Ampligen (rintatolimod) as a potential treatment for Myalgic encephalomyelitis/chronic...
Stock Information
Recent SEC Filings
Corporate Presentation